PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Kyushu University
Updated on 24 April 2021


This is an open-label, single-arm phase I/II trial to evaluate the safety and efficacy of Rho-associated protein kinase(ROCK) inhibitor Ripasudil eye drops for preterm infants with Retinopathy of Prematurity(ROP).


Ripasudil eye drops will be administrated to all enrolled preterm infants with zone I/II stage 1 or greater ROP except for aggressive posterior ROP, Type1 ROP .

The safety and efficacy of ripasudil in treated patients will be assessed in comparison to a historical control.

Condition Retinopathy of Prematurity
Treatment Ripasudil ophthalmic solution 0.4%
Clinical Study IdentifierNCT04621136
SponsorKyushu University
Last Modified on24 April 2021


Yes No Not Sure

Inclusion Criteria

\. Informed consent signed by parents or legal guardians of the patient
\. Patients born with less than or equal to 32 weeks of gestational age and/or less than or equal to 1,500 grams of birth weight
\. Patients with the following types of ROP in both eyes
Zone I ROP with stage greater than or equal to 1
Zone II ROP with stage greater than or equal to 1

Exclusion Criteria

\. Patients with aggressive posterior ROP in one or both eyes
\. Patients with type 1 ROP in one or both eyes
\. Patients with a confirmed or suspected chromosomal abnormality or genetic disorder
\. History of hypersensitivity to ripasudil (including drugs with similar chemical structure) in patients or their mothers
\. Patients or their mothers have participated in another intervention study and have used the study drug of another intervention study within 30 days prior to enrollment in this study or within 5 times the half-life of the study drug
\. Patients with an ocular structural abnormality that can affect the evaluation of this clinical study by investigators
\. Patients with a clinically significant neurological disease (e.g., intraventricular hemorrhage grade 3 or higher, severe hydrocephalus with significantly increased intracranial pressure)
\. Patients with inadequate blood access
\. Patients with complications, allergies, or worsening systemic conditions that make it difficult to conduct this trial
\. Patients judged unsuitable by investigators
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note